Handelsavisen
prelaunch
Companies Healthcare KIDS.O
KI
KIDS.O NASDAQ Health Care Equipment & Supplies

Kids.O

$20,87
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
523,7M USD
P/E
EV / Rev
2,4x
Div yield
Op margin
-15,0 %
ROE
-11,5 %
Net margin
-16,3 %
Debt / equity
0,29
Beta
52w range
Volume
Day range
Prev close
$20,11
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Orthopediatrics Corp (KIDS.O) operates in the Medical Equipment & Supplies industry, generating revenue through the sale of medical devices, though specific product lines are not detailed in the available data.

Business. Orthopediatrics Corp (KIDS.O) operates in the Medical Equipment & Supplies industry, generating revenue through the sale of medical devices, though specific product lines are not detailed in the available data.

Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
Generated · model-assisted
Sell-side consensus
BUY9 analysts
8 buy1 hold0 sell
Avg 12m price target25,00

Analyst recommendations

9 analysts · consensus Buy
Buy8
Hold1
Sell0
12-month price target
25,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
9 analysts · indicative
Ownership
Wellington Management Company, LLP
largest disclosed fund holder
Profitability
-11,5 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning KIDS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to KIDS.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Orthopediatrics Corp (KIDS.O) operates in the Medical Equipment & Supplies industry, generating revenue through the sale of medical devices, though specific product lines are not detailed in the available data.

    Classification85 %
    SectorHealth Care
    Industry groupHealth Care Equipment & Supplies
    AI synthesis
    GENERATED

    Orthopediatrics Corp maintains a capital structure characterized by moderate leverage and negative net cash. The company holds $19.6 million in cash and equivalents against $99.8 million in long-term debt, resulting in a debt-to-equity ratio of 0.29. This leverage profile is supported by a total equity base of $346.6 million and total assets of $508.6 million. The current ratio is not explicitly provided, but the negative net cash position flags a medium liquidity risk, indicating that the company relies on external financing or future cash flow generation to meet obligations.

    Profitability metrics indicate significant operational challenges, with the company reporting a net loss of $39.6 million on revenues of $236.3 million. The gross profit of $172.7 million suggests a gross margin of approximately 73%, which is typical for specialized medical device manufacturers, but operating expenses exceed gross profit, leading to an operating loss of $39.2 million. Return on equity stands at -11.45% and return on assets at -7.8%, reflecting the inability to generate positive returns on invested capital in the current period. The negative EV/EBITDA of -15.98 further underscores the lack of earnings before interest, taxes, depreciation, and amortization.

    Revenue concentration by segment or geography is not disclosed in the available data. The company’s total revenue of $236.3 million represents its entire top-line performance for the latest normalized period. Without segment breakdowns, it is not possible to assess the diversification of revenue streams or geographic exposure risks.

    Growth trajectory analysis is limited due to the absence of historical period data. The current revenue figure of $236.3 million serves as the baseline for performance evaluation. Without year-over-year or quarter-over-quarter comparisons, the direction and magnitude of revenue growth cannot be determined from the provided inputs.

    Risk assessment highlights medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, which may constrain financial flexibility. The low dilution risk suggests that the company is not currently engaging in significant equity issuance, supported by the identical basic and diluted share counts of 25.1 million.

    Recent events include analyst coverage updates with a mean price target of $25.00 and a median target of $24.00, indicating a potential upside from the current market price of $20.11. The mean recommendation of 1.89 suggests a bullish sentiment among analysts, with 2 strong buys and 6 buys recorded. No specific news events or filing observations were provided beyond the reconciler enqueue notifications.

    Key takeaways
    • Orthopediatrics Corp reports a net loss of $39.6 million on $236.3 million in revenue, indicating significant operational inefficiencies.
    • The company carries $99.8 million in long-term debt against $19.6 million in cash, resulting in a negative net cash position and medium liquidity risk.
    • Analyst sentiment is positive, with a mean price target of $25.00 and a mean recommendation of 1.89, suggesting expected future improvements.
    • Return on equity is -11.45% and return on assets is -7.8%, reflecting poor capital efficiency in the current period.
    • Dilution risk is low, with no difference between basic and diluted share counts, indicating stable equity structure.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-04-30
    Q1 2026 · Quarter highlights
    Open report →

    Revenue $59.4M, +13,3% YoY; Operating income +24,1% YoY.

    Revenue$59.4M+13,3 % YoY
    Operating income-$8.3M+24,1 % YoY
    Net income-$10.7M−0,3 % YoY
    Free cash flow-$6.7M+31,6 % YoY
    EPS
    Operating cash flow-$3.3M+20,9 % YoY
    Financials
    Income statement
    Revenue$59.4M
    Gross profit$43.4M
    Operating income-$8.3M
    Net income-$10.7M
    Margins
    Gross margin73.1%
    Operating margin-14.0%
    Net margin-18.0%
    FCF margin-11.3%
    Balance sheet
    Total assets$502.2M
    Total liabilities$163.5M
    Total equity$338.7M
    Cash & equivalents$36.6M
    Long-term debt$100.6M
    Cash flow
    Operating cash flow-$3.3M
    CapEx-$1.8M
    Free cash flow-$6.7M
    SBC
    P&L flow · revenue → net income
    Revenue $59.4MOperating costs $67.7MTax $2.4MNet income $10.7M
    Highlights
    • Revenue $59.4M, +13,3% YoY
    • Operating income +24,1% YoY
    • Net income −0,3% YoY
    • Free cash flow +31,6% YoY
    • Net margin -18.0%

    Valuation TTM

    Market price
    $20,87
    Market cap
    $504.6M
    Enterprise value
    $584.9M
    P/E
    Non-GAAP P/E
    EV / Revenue
    2.4x
    EV / Op income
    EV / OCF
    P / B
    1.5x
    P / Tangible book
    1.5x
    Tangible book
    $346.6M
    Net cash
    -$80.3M
    Current ratio
    Debt / equity
    0.3
    ROA
    -7.8%
    ROE
    -11.5%
    Cash conversion
    12.0%
    CapEx / revenue
    -4.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships32 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries32
    EX21:010aea022addEX21:010aea022addSubsidiarie97%
    EX21:04ab6b7960f1EX21:04ab6b7960f1Subsidiarie97%
    EX21:06f91e6329d4EX21:06f91e6329d4Subsidiarie97%
    EX21:0e180491d5feEX21:0e180491d5feSubsidiarie97%
    EX21:21262a3cb533EX21:21262a3cb533Subsidiarie97%
    EX21:258d7b83d2edEX21:258d7b83d2edSubsidiarie97%
    EX21:2f4d990978bdEX21:2f4d990978bdSubsidiarie97%
    EX21:300326a92dacEX21:300326a92dacSubsidiarie97%
    EX21:33c39803ccc3EX21:33c39803ccc3Subsidiarie97%
    EX21:3c6155426d9cEX21:3c6155426d9cSubsidiarie97%
    EX21:49ea9faaa0ecEX21:49ea9faaa0ecSubsidiarie97%
    EX21:4a83b94ff22eEX21:4a83b94ff22eSubsidiarie97%
    EX21:4c172c298506EX21:4c172c298506Subsidiarie97%
    EX21:54ab090cf713EX21:54ab090cf713Subsidiarie97%
    EX21:5edf805ca2ceEX21:5edf805ca2ceSubsidiarie97%
    EX21:6bba8f70bc2cEX21:6bba8f70bc2cSubsidiarie97%
    EX21:7c09e502771fEX21:7c09e502771fSubsidiarie97%
    EX21:7fac036e3502EX21:7fac036e3502Subsidiarie97%
    EX21:a06fabc28a68EX21:a06fabc28a68Subsidiarie97%
    EX21:a721fb8ccde3EX21:a721fb8ccde3Subsidiarie97%
    EX21:a900faf92bd5EX21:a900faf92bd5Subsidiarie97%
    EX21:a9c31b29a3caEX21:a9c31b29a3caSubsidiarie97%
    EX21:c17f3d6b09e6EX21:c17f3d6b09e6Subsidiarie97%
    EX21:c279846e24b2EX21:c279846e24b2Subsidiarie97%
    EX21:c90038235552EX21:c90038235552Subsidiarie97%
    EX21:cbcb3d1c587bEX21:cbcb3d1c587bSubsidiarie97%
    EX21:cf0ecc2ff2d1EX21:cf0ecc2ff2d1Subsidiarie97%
    EX21:d723236952baEX21:d723236952baSubsidiarie97%
    EX21:df8eba5ff2e0EX21:df8eba5ff2e0Subsidiarie97%
    EX21:eca237358458EX21:eca237358458Subsidiarie97%
    EX21:f1b6e370a157EX21:f1b6e370a157Subsidiarie97%
    EX21:f8d3ad90c3a4EX21:f8d3ad90c3a4Subsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -1,18
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    9
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-07-31 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-1,18
    Revenueno estimateno estimate265,2M USD
    Operating incomeno estimateno estimate-18,3M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution9 analysts
    Strong buy2
    Buy6
    Hold1
    Sell0
    Strong sell0
    12-month price target$25,00 · Median $24,00
    Low $20,00High $34,00
    Operating income · consensus-18,3M USD
    EPS surprise
    −42,7 %
    reported vs consensus · miss
    Revenue surprise
    −10,9 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$20,00
    Mean$25,00
    Median$24,00
    High$34,00
    Spot$20,87
    +19.8 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-15,0 %Bottom quartile
    Net Margin-16,3 %Bottom quartile
    ROE-11,5 %Below median
    Capex / Rev-4,6 %Below median
    D/E0,29Below median
    Cash Conv0,12Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • OrthoPediatrics Corp Market data — financials · 2026-07-31
    • reconciler_enqueue (reconciler) on KIDS.O · 2026-07-31
    • OrthoPediatrics Corp Market data — analyst estimates · 2026-07-31
    • OrthoPediatrics Corp Market data — ESG · 2026-07-31
    • KIDS.O HA canonical relationships · 2026-07-31

    Ownership & reference

    Top holders

    • Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$14M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$9M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$18M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$37M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$5M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$7M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$2M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$17M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$1M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$7M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$1M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$1M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • David R. BaileyPresident, Chief Executive Officer, Director

    Insider activity

    Net selling1 buys · 5 sellsnet -$905K14 insiders · last 365d
    • Pelizzon David RDirector · Common StockOther 11 436 · 2026-06-09
    • Hughes Bryan WDirector · Common StockOther 11 436 · 2026-06-09
    • Fischer Kelly LaineDirector · Common StockOther 11 436 · 2026-06-09
    • Riccitelli Samuel DDirector · Common StockOther 11 436 · 2026-06-09
    • Ruf HaroldDirector · Common StockOther 11 436 · 2026-06-09
    • Bailey David RDirector, President and CEO · Common StockOther 119 140 · 2026-06-09
    • McDonald Jimmy DuaneDirector · Common StockOther 11 436 · 2026-06-09
    • Infante (Reynolds) Marie CDirector · Common StockOther 11 436 · 2026-06-09
    • Throdahl Mark CDirector · Common StockOther 11 436 · 2026-06-09
    • Dyer George Sinclair MitchellDirector · Common StockOther 11 436 · 2026-06-09
    • Gerritzen Daniel JGeneral Counsel and Secretary · Common StockOther 2 479 · 2026-05-13
    • Hite FredDirector, COO and CFO · Common StockSold 12 993 @ $17,25$224K · 2026-03-16
    • Gerritzen Daniel JGeneral Counsel and Secretary · Common StockSold 8 614 @ $17,25$149K · 2026-03-16
    • Hauser Joseph WPres. Trauma & Def. Correction · Common StockSold 8 596 @ $17,25$148K · 2026-03-16
    • Odle Gregory APresident of Scoliosis · Common StockSold 8 433 @ $17,25$145K · 2026-03-16
    • Bailey David RDirector, President and CEO · Common StockSold 19 535 @ $17,25$337K · 2026-03-16
    • Hite FredDirector, COO and CFO · Common StockOther 77 405 · 2026-03-15
    • Hauser Joseph WPres. Trauma & Def. Correction · Common StockOther 65 700 · 2026-03-15
    • Odle Gregory APresident of Scoliosis · Common StockOther 47 380 · 2026-03-15
    • Gerritzen Daniel JGeneral Counsel and Secretary · Common StockOther 47 380 · 2026-03-15
    • Bailey David RDirector, President and CEO · Common StockOther 1 600 · 2025-12-29
    • Fischer Kelly LaineDirector · Common StockOther 4 345 · 2025-11-10
    • Hite FredDirector, COO and CFO · Common StockBought 5 076 @ $19,41$99K · 2025-08-21

    Short positioning

    881.3Kshares short-1.6% vs prior
    6.2days to cover
    41.3%short of daily vol
    99fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    KIDS.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    KIDSEX21:010EX21:04aEX21:06fEX21:0e1EX21:212EX21:258EX21:2f4EX21:300EX21:33cEX21:3c6Health Care Eq
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Current assets (annual): USD 256.42MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -2Unknown
    • Shares outstanding (annual): 25.09MUnknown
    • Cost of revenue (annual): USD 63.69MUnknown
    • Revenue (annual): USD 236.35MUnknown
    • Total liabilities (annual): USD 162.03MUnknown
    • Operating cash flow (annual): USD -4.85MUnknown
    • Operating income (annual): USD -39.24MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -2Unknown
    • Net income (annual): USD -39.65MUnknown
    • Gross profit (annual): USD 172.66MUnknown
    • Current liabilities (annual): USD 46.2MUnknown
    • Shareholders' equity (annual): USD 346.6MUnknown
    • Cash & equivalents (annual): USD 19.56MUnknown
    • Long-term debt (annual): USD 106.01MUnknown
    • R&D expense (annual): USD 9.1MUnknown
    • Total operating expenses (annual): USD 211.9MUnknown
    • Pre-tax income (annual): USD -39.19MUnknown
    • Capex (annual): USD 11.11MUnknown
    • Total assets (annual): USD 508.63MUnknown
    • Total liabilities (annual): USD 118.64MUnknown
    • Long-term debt (annual): USD 77.48MUnknown
    • Gross profit (annual): USD 148.6MUnknown
    • Revenue (annual): USD 204.73MUnknown
    Showing 24 of 38 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-08-04 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
    2026-08-04EVENTUpcomingQ2 2026 earnings (expected) estimated date
    2026-06-09 00:00 UTCINSIDER10 insider transactions — 2026-06
    2026-06-09 00:00 UTCINSIDER10 insider transactions — 2026-06
    2026-06-09INSIDERPelizzon David R transacted 11.4k sh — Director
    2026-06-09INSIDERHughes Bryan W transacted 11.4k sh — Director
    2026-06-09INSIDERFischer Kelly Laine transacted 11.4k sh — Director
    2026-06-09INSIDERRiccitelli Samuel D transacted 11.4k sh — Director
    2026-06-09INSIDERRuf Harold transacted 11.4k sh — Director
    2026-06-09INSIDERBailey David R transacted 119.1k sh — Director, President and CEO
    2026-06-09INSIDERMcDonald Jimmy Duane transacted 11.4k sh — Director
    2026-06-09INSIDERInfante (Reynolds) Marie C transacted 11.4k sh — Director
    2026-06-09INSIDERThrodahl Mark C transacted 11.4k sh — Director
    2026-06-09INSIDERDyer George Sinclair Mitchell transacted 11.4k sh — Director
    2026-06-04FILING8-K filing →
    2026-05-13 00:00 UTCINSIDER1 insider transaction — 2026-05
    2026-05-13 00:00 UTCINSIDER1 insider transaction — 2026-05
    2026-05-13INSIDERGerritzen Daniel J transacted 2.5k sh — General Counsel and Secretary
    2026-05-01FILING10-Q filing →
    2026-04-30 16:05 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 59.4M · Net USD -10.7M
    2026-04-30FILING8-K filing →
    2026-04-30FILING8-K filing →
    2026-04-20FILINGDEF 14A filing →
    2026-04-01FILINGFORM 8-K →
    2026-03-16 00:00 UTCINSIDER9 insider transactions — 2026-03 · net sell $1.0M
    2026-03-16 00:00 UTCINSIDER9 insider transactions — 2026-03 · net sell $1.0M
    2026-03-16INSIDERHite Fred sold 13.0k sh — Director, COO and CFO ~$224k
    2026-03-16INSIDERGerritzen Daniel J sold 8.6k sh — General Counsel and Secretary ~$149k
    2026-03-16INSIDERHauser Joseph W sold 8.6k sh — Pres. Trauma & Def. Correction ~$148k
    2026-03-16INSIDEROdle Gregory A sold 8.4k sh — President of Scoliosis ~$145k
    2026-03-16INSIDERBailey David R sold 19.5k sh — Director, President and CEO ~$337k
    2026-03-15INSIDERHite Fred transacted 77.4k sh — Director, COO and CFO
    2026-03-15INSIDERHauser Joseph W transacted 65.7k sh — Pres. Trauma & Def. Correction
    2026-03-15INSIDEROdle Gregory A transacted 47.4k sh — President of Scoliosis
    2026-03-15INSIDERGerritzen Daniel J transacted 47.4k sh — General Counsel and Secretary
    2026-03-04FILING10-K filing →
    2026-02-26 16:05 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 61.6M · Net USD -10.1M
    2026-02-26 16:05 UTCEARNINGSAnnual results — FY 2026 Revenue USD 236.3M · Net USD -39.6M
    2026-02-26FILING8-K filing →
    Showing the 40 most recent of 59 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage